Laura Mariani is a Nephrology physician affiliated with University of Michigan. OpenAlex indexes 283 publications with 6,455 citations (h-index 29).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
3rd Floor Taubman Center Recp C
Ann Arbor, MI 481095000
Telephone
734-936-5548Registry record last updated 16 Jan 2013.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Travere Therapeutics, Inc.Program year202511 payments$17,398openpaymentsdata.cms.gov ↗
- Apellis Pharmaceuticals, Inc.Program year20252 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20243 payments$93,901openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
73.8%Angiotensin receptor blocker (ARB)23.4%Losartan Potassium100%Part D<11 patientsCalcium channel blocker19.1%Amlodipine Besylate100%Part D<11 patients+ 2 more classes in this area
Musculoskeletal
9.2%Xanthine oxidase inhibitor9.2%Allopurinol100%Part D<11 patientsMetabolism & gastrointestinal
8.5%H2 blocker8.5%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Digital Pathology and Computational Image Analysis for Lupus Nephritis
University of Michigan at Ann Arbor
FY2026$582,026R01AR080668
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/Vasculitis
Clinical Journal of the American Society of Nephrology
2025 - Elevated Exposure to Air Pollutants Accelerates Primary Glomerular Disease Progression
Kidney International Reports
2024 - Clinical Relevance of Computational Pathology Analysis of Interplay between Kidney Microvasculature and Interstitial Microenvironment
Clinical Journal of the American Society of Nephrology
2024 - An integrated organoid omics map extends modeling potential of kidney disease
Nature Communications
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Moshe Talpaz, MD
University of Michigan
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”